BACKGROUND: Recent diagnostic procedure advances have greatly improved early lung cancer detection. However, the invasive, unpleasant and inconvenient nature of current diagnostic procedures limits their application. There is a great need of novel non-invasive biomarkers for early lung cancer diagnosis. In the present study, we intend to determine whether the blood signatures of p14ARF promoter methylation are suitable for early detection of lung cancer. METHODS: The study aimed to assess the probability of p14ARF promoter methylation in plasma samples to detect early lung cancer using nested methylation-specific PCR in the training set consisted of tumor tissues and paired blood. Besides, we were further to discuss the difference in time to progression between methylation and unmethylation of p14ARF promoter using univariate and multivariate analysis. RESULTS: The methylation of p14ARF promoter was detected in 33.6 % of tumor tissues, and 12.1 and 25.2 % in distant-cancer mucosa and matched plasma, respectively, and our study has also demonstrated the positive correlation between them by Pearson's test (r = 0.300). The tumor-free survival time of the unmethylation of p14ARF promoter is significantly longer than that of the methylation of p14ARF promoter in tumor tissues (χ (2) = 7.149, P = 0.008). CONCLUSION: The methylation of p14ARF promoter in plasma samples has strong potential as a novel non-invasive biomarker for early detection of lung cancer, and the methylation of p14ARF promoter was considered as prognostic factor in our study.
BACKGROUND: Recent diagnostic procedure advances have greatly improved early lung cancer detection. However, the invasive, unpleasant and inconvenient nature of current diagnostic procedures limits their application. There is a great need of novel non-invasive biomarkers for early lung cancer diagnosis. In the present study, we intend to determine whether the blood signatures of p14ARF promoter methylation are suitable for early detection of lung cancer. METHODS: The study aimed to assess the probability of p14ARF promoter methylation in plasma samples to detect early lung cancer using nested methylation-specific PCR in the training set consisted of tumor tissues and paired blood. Besides, we were further to discuss the difference in time to progression between methylation and unmethylation of p14ARF promoter using univariate and multivariate analysis. RESULTS: The methylation of p14ARF promoter was detected in 33.6 % of tumor tissues, and 12.1 and 25.2 % in distant-cancer mucosa and matched plasma, respectively, and our study has also demonstrated the positive correlation between them by Pearson's test (r = 0.300). The tumor-free survival time of the unmethylation of p14ARF promoter is significantly longer than that of the methylation of p14ARF promoter in tumor tissues (χ (2) = 7.149, P = 0.008). CONCLUSION: The methylation of p14ARF promoter in plasma samples has strong potential as a novel non-invasive biomarker for early detection of lung cancer, and the methylation of p14ARF promoter was considered as prognostic factor in our study.
Authors: Kimberly Laskie Ostrow; Mohammad O Hoque; Myriam Loyo; Marianna Brait; Alissa Greenberg; Jill M Siegfried; Jennifer R Grandis; Autumn Gaither Davis; William L Bigbee; William Rom; David Sidransky Journal: Clin Cancer Res Date: 2010-06-30 Impact factor: 12.531
Authors: Masatsugu Hamaji; Mark S Allen; Stephen D Cassivi; Claude Deschamps; Francis C Nichols; Dennis A Wigle; K Robert Shen Journal: J Thorac Cardiovasc Surg Date: 2013-03 Impact factor: 5.209
Authors: Duk-Hwan Kim; Jin Seuk Kim; Jung-Ho Park; Suk Kyoo Lee; Yong-Ick Ji; Young Mi Kwon; Young Mog Shim; Joungho Han; Joobae Park Journal: Cancer Res Date: 2003-10-01 Impact factor: 12.701
Authors: Mathewos Tessema; Randy Willink; Kieu Do; Yang Y Yu; Wayne Yu; Emi O Machida; Malcolm Brock; Leander Van Neste; Christine A Stidley; Stephen B Baylin; Steven A Belinsky Journal: Cancer Res Date: 2008-03-15 Impact factor: 12.701
Authors: Lela Buckingham; L Penfield Faber; Anthony Kim; Michael Liptay; Carter Barger; Sanjib Basu; Mary Fidler; Kelly Walters; Philip Bonomi; John Coon Journal: Int J Cancer Date: 2010-04-01 Impact factor: 7.396